We subsequently measured the expression levels of ADAMTS9-AS2 in clinical neuroblastoma samples, and the results showed that the expression of ADAMTS9-AS2 was markedly lower in patients with stage 4 tumors compared with in patients with stage 1 or stage 2 and 3 tumors (Figure 1B). This evidence concerns the gene ADAMTS9 and neuroblastoma.